Virtus ETF Advisers LLC Gritstone Bio, Inc. Transaction History

Virtus ETF Advisers LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.77 - $4.34 $23,962 - $58,754	-13,538 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.03 - $12.19 $3,256 - $9,849	-808 Reduced 5.63%	13,538 $56,000
Q4 2021 Feb 14, 2022	SELL	$8.76 - $13.71 $56,861 - $88,991	-6,491 Reduced 31.15%	14,346 $184,000
Q3 2021 Nov 15, 2021	SELL	$6.41 - $13.54 $7,006 - $14,799	-1,093 Reduced 4.98%	20,837 $225,000
Q2 2021 Aug 10, 2021	BUY	$8.13 - $10.2 $178,290 - $223,685	21,930 New	21,930 $200,000
Q4 2019 Feb 13, 2020	SELL	$7.07 - $11.61 $181,684 - $298,353	-25,698 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$8.45 - $12.28 $12,100 - $17,584	-1,432 Reduced 5.28%	25,698 $222,000
Q2 2019 Aug 13, 2019	BUY	$9.2 - $15.7 $249,595 - $425,941	27,130 New	27,130 $302,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.